ITeos Therapeutics Inc Ordinary Shares ITOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ITOS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $14.02
- Day Range
- $13.87–14.67
- 52-Week Range
- $8.20–18.75
- Bid/Ask
- $14.35 / $14.66
- Market Cap
- $529.56 Mil
- Volume/Avg
- 444,540 / 441,258
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 157
Comparables
Valuation
|
Metric
|
ITOS
|
ACLX
|
LYEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.97 | 5.98 | 0.68 |
Price/Sales | — | 20.99 | 6,000.00 |
Price/Cash Flow | — | 411.35 | — |
Price/Earnings
ITOS
ACLX
LYEL
Financial Strength
|
Metric
|
ITOS
|
ACLX
|
LYEL
|
|---|---|---|---|
Quick Ratio | 12.80 | 5.32 | 16.27 |
Current Ratio | 13.51 | 5.46 | 16.51 |
Interest Coverage | — | −22.10 | — |
Quick Ratio
ITOS
ACLX
LYEL
Profitability
|
Metric
|
ITOS
|
ACLX
|
LYEL
|
|---|---|---|---|
Return on Assets (Normalized) | −16.56% | −1.99% | −21.31% |
Return on Equity (Normalized) | −18.86% | −3.75% | −24.24% |
Return on Invested Capital (Normalized) | −22.78% | −7.24% | −25.73% |
Return on Assets
ITOS
ACLX
LYEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Vhqpmgphjs | Vsvh | $636.3 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rnztkvjtn | Vtjdtp | $124.4 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wltgzqy | Rccjd | $115.9 Bil | |||
| Moderna Inc
MRNA
| Hjrrdwkb | Xlhn | $44.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qqhptsjs | Qjpcfvc | $32.3 Bil | |||
| argenx SE ADR
ARGX
| Gsgxlzkjf | Qpms | $25.8 Bil | |||
| BioNTech SE ADR
BNTX
| Dfkdpqfv | Gdgw | $19.4 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vrqzhydc | Qxsxwwm | $15.7 Bil | |||
| United Therapeutics Corp
UTHR
| Mkszjzz | Dtq | $14.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Zglvkmhvjm | Kchgrm | $11.6 Bil |